Formally Common, Nationally Unequal: Methodological Asymmetry in EU Joint Clinical Assessment

1. Introduction

The Joint Clinical Assessment (JCA) created by Regulation (EU) 2021/2282 is usually described as a shared technical platform: a scientific analysis of the relative clinical effects of a new medicine, including the degree of certainty of those effects, to which every Member State must “give due consideration” in its own health technology assessment under Article 13 of the Regulation [1,2]. Mandatory since January 2025 for new oncology medicines and advanced-therapy products, and set to widen over this decade toward all centrally authorised medicines, the JCA is expected progressively to shape the evidence base on which national decisions rest [1]. Whether that expectation is borne out in practice remains to be seen. Framed this way, the JCA appears procedurally neutral, a common input that leaves national decision-making untouched. This correspondence argues that the neutrality is only apparent. The significance of the JCA lies not only in what it assesses, but in how its conclusions interact with the decision rules of each national system. Because those rules differ profoundly [3], an identical JCA report will not carry identical consequences. Some systems can absorb, reinterpret, contextualise or model around a JCA conclusion; others, Germany most conspicuously, may retain less room to accommodate a divergent characterisation of the evidence when a JCA judgement on evidence certainty or relative effect sits uneasily with established national assessment rules.

The central asymmetry is that the JCA may be formally common yet nationally unequal in its consequences. In Germany, where the added-benefit assessment is tightly structured around the certainty of evidence, confidence intervals, endpoint categories and the procedural rules that govern how these elements are appraised, a JCA conclusion on certainty and effect magnitude may exert stronger practical influence over the national process that follows. In systems organised around broader deliberation, public-health judgement, cost-effectiveness modelling or innovativeness frameworks, the same conclusion enters a wider appraisal logic that retains discretion to weigh, qualify or offset it. This does not mean that the JCA legally predetermines national conclusions. The Regulation makes the JCA report non-binding, preserves each Member State’s competence to draw its own conclusions on the clinical added value of a technology, and permits complementary national analyses; where the national PICO or clinical context differs, a Member State may justifiably rely on complementary national analyses or draw a different national conclusion on clinical added value, provided it reports how the JCA report was given due consideration [1,2]. The asymmetry is therefore practical and epistemic rather than legal: it concerns how much interpretive room each system retains once the JCA has framed the evidence.

2. Methodological Asymmetry Across National HTA Systems

Germany occupies the high-exposure end of this spectrum for structural, not political, reasons. The Institute for Quality and Efficiency in Health Care (IQWiG) dossier assessment is among the most standardised in Europe [4,5]. That assessment is prepared by IQWiG, a private scientific institute commissioned by the Federal Joint Committee (G-BA), which must observe the procedural rules the G-BA itself lays down and which holds no decision-making authority of its own. The extent of added benefit and the certainty of the underlying conclusions are derived, through those rules, from the effect estimates, the position of their confidence-interval limits, and the endpoint category concerned — mortality, morbidity, health-related quality of life, or adverse events [4]. In this operationalisation the confidence interval is not a peripheral descriptor but part of what determines the recorded magnitude of added benefit. The dossier assessment therefore follows a highly structured path from clinical inputs to a benefit category, but it does so within the rules the G-BA has set for it. The G-BA, for its part, conducts its own procedure, including consultation, and adopts the final resolution, which may modify the IQWiG conclusion before it feeds into the subsequent price negotiation [5,6]. Empirical analyses nonetheless show substantial concordance between the two bodies: IQWiG has reported agreement on the extent of added benefit in roughly 70% of cases [7], while analyses of the binary recognition of any added benefit have found that the G-BA more often granted an added benefit where IQWiG had not than the reverse [8,9]. Such concordance is in large part a corollary of the requirement that IQWiG work within the G-BA’s procedural rules, rather than evidence of IQWiG influence over the G-BA; where the two diverge, it is typically because the G-BA additionally weighs considerations such as feasibility in routine care. The point is not that the German decision is automatic, but that its deliberative stage operates on an evidentiary characterisation that the rule-structured dossier assessment, conducted under the G-BA’s own procedural rules, has already largely shaped, and that this characterisation is expressed in the same vocabulary the JCA uses, concerning relative effects, statistical precision (confidence intervals), endpoint-specific outcomes and graded certainty [5]. Where the common assessment and the national anchor already describe the evidence in the same terms, the room for a materially different clinical characterisation may be narrower than in systems where the JCA is only one input into a broader deliberative or economic appraisal.

Other national systems retain broader appraisal routes through which to contextualise a JCA conclusion within their own value frameworks. In France, the Transparency Committee expresses clinical benefit and added clinical benefit through the SMR and ASMR ratings, using a deliberative judgement that integrates efficacy, safety, disease severity, therapeutic strategy burden of illness, unmet needs, and public-health interest, as set out in its published doctrine [10]; a JCA conclusion informs that judgement but does not determine it. In Italy, AIFA assesses innovativeness by combining therapeutic need, added therapeutic value and the quality of clinical evidence, the last graded through the GRADE methodology, an independent evidentiary layer with its own standards [11]; the JCA may inform the clinical-effectiveness input, but the innovativeness verdict is reached deliberatively and can diverge. Systems with a formal economic-evaluation component, such as the Netherlands, Ireland, Belgium and several Nordic systems, occupy a distinct position: residual clinical uncertainty from the JCA may be represented in cost effectiveness model-based analyses, including deterministic, probabilistic and scenario sensitivity analyses around the incremental cost-effectiveness ratio, rather than being treated solely as a binary evidentiary barrier, in line with standard national economic-evaluation guidance [12]. Consistent with this graded picture, matched-drug-pair analyses have found German and French appraisals more concordant with one another than with the English, potentially illustrating that incorporation of economic evaluation is associated with more restrictive recommendations [13,14]. Across these systems the common thread is a deliberative or analytic stage capable of reinterpreting a JCA conclusion, the interpretive room that the rule-structured German anchor affords less readily.

This asymmetry carries an implication beyond any single country. If JCA conclusions on evidence certainty, indirect comparisons, surrogate-endpoint validation, multiplicity, subgroup evidence or the maturity of survival data come to exert influence across Europe, then the methodological guidance underpinning those conclusions is not a purely technical matter; it becomes a site of institutional consequence, because the choice of method determines which national traditions find the common assessment congenial and which must work against it. The relevant question is not whether any Member State formally controls the JCA, but whether its methodological architecture is more readily operationalised by some national assessment traditions than by others. The concern is not intentional alignment with any one Member State, but the possibility that a common methodology may create unequal friction across national HTA systems. Framed this way, the issue is one of methodological compatibility and institutional path dependence rather than of control: shared methods, once embedded in templates and guidance, tend to persist and to structure the field of acceptable evidence and argument [15,16,17]. Comparative work on relative effectiveness assessments produced under EUnetHTA has already reported high heterogeneity across national appraisals of the same underlying evaluation, not only concerning results but also the underlying methodology [18], a reminder that a common assessment does not translate mechanically into common conclusions.

The broader concern follows directly. EU-HTA harmonisation is intended to reduce duplication and to raise the quality and consistency of clinical assessment, and in important respects it can be expected to do so. But a common clinical assessment does not have neutral consequences when national appraisal systems differ in their capacity to reinterpret, contextualise or model uncertainty. Apparent harmonisation at the assessment stage may coexist with, and even conceal, a real asymmetry at the appraisal stage, one in which the systems whose methods most resemble the common framework operate with least friction, while others expend interpretive effort to reconcile a shared conclusion with a different decision logic. The risk is not that harmonisation fails visibly, but that it succeeds unevenly: uniform in form, divergent in the latitude it leaves to each Member State.

Several measures would help the JCA carry its methodological choices transparently and serve rule-based and deliberative systems alike, consistent with established principles for the transparent conduct of HTA [19]. First, JCA reports could maintain a clear separation between the description of the evidence, the judgement about its certainty, and any interpretive consequences that follow, so that national appraisers can engage each layer on its own terms rather than inheriting a bundled conclusion. Second, JCA guidance could explicitly recognise downstream national heterogeneity, acknowledging that an identical report will be operationalised differently across Member States. Third, the HTA Coordination Group could make transparent how divergent national methodological traditions were considered when guidance was developed, and where trade-offs between them were made. None of this requires adjudicating which national method is superior, a question this letter deliberately leaves open; the aim is procedural legitimacy, so that methodological choices which may advantage or constrain particular systems can be debated openly rather than settled implicitly.

3. Discussion and Conclusion

The success of EU-HTA will not be determined solely by whether Member States give “due consideration” to JCA reports, a formal obligation that says little about substantive uptake. It will depend on whether the common framework is perceived as methodologically balanced, procedurally transparent and sufficiently neutral across national HTA traditions. Germany may have more at stake than other Member States, not because of any privileged position, but because its national process is more tightly coupled to the evidentiary elements a JCA report is expected to describe relative effects, uncertainty, endpoint categories and certainty of conclusions. That asymmetry, a common assessment meeting unequal national capacities to absorb it, deserves explicit discussion now, while JCA practice is still being established and before early reports harden into methodological precedent. Whether JCA will truly harmonize clinical assessment or merely shift existing heterogeneity to the next stage of national appraisal, remains to be seen.